HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cyrus R Mehta Selected Research

alogliptin

8/2018Total cardiovascular events analysis of the EXAMINE trial in patients with type 2 diabetes and recent acute coronary syndrome.
5/2017Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care).
1/2017Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
7/2016Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
5/2016Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial.
1/2016Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin.
5/2015Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
10/2013Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Cyrus R Mehta Research Topics

Disease

9Type 2 Diabetes Mellitus (MODY)
12/2018 - 10/2013
8Acute Coronary Syndrome
08/2018 - 10/2013
3Unstable Angina
08/2018 - 10/2013
3Stroke (Strokes)
08/2018 - 05/2015
3Cardiovascular Diseases (Cardiovascular Disease)
11/2017 - 05/2015
3Heart Failure
11/2017 - 05/2015
3Myocardial Infarction
01/2016 - 10/2013
2Coronary Disease (Coronary Heart Disease)
01/2017 - 01/2016
2Hypoglycemia (Reactive Hypoglycemia)
02/2015 - 10/2013
2Parkinson Disease (Parkinson's Disease)
06/2009 - 12/2007
1Chemical and Drug Induced Liver Injury
12/2018
1Pain (Aches)
06/2018
1Hypotension (Low Blood Pressure)
02/2015
1Hemangioma (Angioma)
02/2015
1Bronchial Spasm
02/2015
1Bradycardia
02/2015
1Body Weight (Weight, Body)
02/2015
1Neoplasms (Cancer)
10/2013
1Pancreatitis
10/2013

Drug/Important Bio-Agent (IBA)

8alogliptinIBA
08/2018 - 10/2013
3Dipeptidyl-Peptidase IV InhibitorsIBA
01/2016 - 10/2013
2omega-Chloroacetophenone (Mace)IBA
01/2017 - 05/2015
2Hypoglycemic Agents (Hypoglycemics)IBA
01/2016 - 10/2013
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
12/2018
1TAK-875IBA
12/2018
1SodiumIBA
11/2017
1empagliflozinIBA
11/2017
1Glucose (Dextrose)FDA LinkGeneric
11/2017
1SymportersIBA
11/2017
1Sodium-Glucose Transporter 2 InhibitorsIBA
11/2017
1Troponin IIBA
05/2017
1Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
05/2017
1Insulin (Novolin)FDA Link
05/2017
1dipeptidaseIBA
05/2016
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2016
1Brain Natriuretic Peptide (Natrecor)FDA Link
05/2015
1Propranolol (Inderal)FDA LinkGeneric
02/2015
1SolutionsIBA
02/2015
1Cardiovascular AgentsIBA
10/2013
1Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA
10/2013

Therapy/Procedure

4Therapeutics
05/2016 - 10/2013
2Deep Brain Stimulation
06/2009 - 12/2007
1Hip Replacement Arthroplasty (Total Hip Replacement)
06/2018